Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROMISE
2023-505626-34-01Phase 4Authorised
- Sponsor
- University Medical Center Groningen
- Start
- Jan 2024
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4 trial of patiromer and irbesartan in chronic kidney disease (CKD) and hypertension (HTN), sponsored by University Medical Center Groningen. Primary endpoint: 24-hour urinary albumin excretion (albumin-creatinine ratio). Planned start Jan 2024; status: authorised.
02
Drugs
patiromerirbesartan
03
Conditions
chronic kidney disease (CKD)hypertension (HTN)
Beyond the preview
Go deeper on 2023-505626-34-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505626-34-01.